Table 1. Selected new targeted therapies in lung cancer. At least 12 clinical trials are testing or plan to test tyrosine kinase inhibitors with activity against recently identified oncogenic drivers of lung cancer in targeted patient populations, including Ret proto-oncogene (RET) fusions, amplifications or mutations in fibroblast growth factor receptors (FGFRs) and discoidin domain receptor tyrosine kinase 2 (DDR2) mutations. Source: ClinicalTrials.gov and University Hospital Medical Information Network.

Compound

Indication

Status

Sponsor

Company collaborator

Clinical trial record

RET fusions

Caprelsa vandetanib

Non-small cell lung cancer (NSCLC)

Phase II

Seoul National University Hospital

AstraZeneca plc (LSE:AZN; NYSE:AZN) 

NCT01823068

Caprelsa

NSCLC

Phase II

National Cancer Center Hospital East

AstraZeneca 

UMIN000010095

Cometriq cabozantinib

NSCLC

Phase II

Memorial Sloan-Kettering Cancer Center

Exelixis Inc. (NASDAQ:EXEL)

NCT01639508

Iclusig ponatinib

NSCLC

Phase II

Massachusetts General Hospital

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) 

NCT01813734

Nexavar sorafenib

NSCLC

Phase II

The Cancer Institute Hospital of JFCR

None

UMIN000007515

DDR2 or BRAF alterations

Sprycel dasatinib

Squamous cell lung cancer

Phase IIA

Dana-Farber Cancer Institute

None

NCT01491633

Sprycel

NSCLC or other cancers

Phase II

Bristol-Myers Squibb Co. (NYSE:BMY) 

None

NCT01514864

FGFR amplifications or mutations

AZD4547B

Breast, squamous lung and stomach cancer

Phase II

The Royal Marsden

AstraZeneca

NCT01795768

AZD4547 plus docetaxel

Squamous cell lung cancer

Phase I/II

Eastern Cooperative Oncology Group

None

NCT01824901

AZD4547

Solid tumors

Phase I

AstraZeneca

None

NCT00979134

Iclusig

Lung and head and neck cancer

Phase II

Dana-Farber

Ariad Pharmaceuticals

NCT01761747

BGJ398B

Solid tumors

Phase I

Novartis AG (NYSE: NVS; SIX:NOVN)

None

NCT01004224

BGJ398

Solid tumors

Phase I (Japan)

Novartis

None

NCT01697605

ATrial was terminated in January 2013 due to safety concerns. BAZD4547 and BGJ398 are selective pan-FGFR inhibitors.